Vanda Pharmaceuticals’ (VNDA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a $18.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com began coverage on Vanda Pharmaceuticals in a report on Monday. They set a “hold” rating for the company.

Vanda Pharmaceuticals Trading Up 3.4 %

Shares of NASDAQ:VNDA opened at $4.51 on Tuesday. Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75. The business has a fifty day simple moving average of $4.81 and a 200 day simple moving average of $5.03. The firm has a market cap of $262.98 million, a price-to-earnings ratio of -16.11 and a beta of 0.77.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now directly owns 44,857 shares in the company, valued at $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 8.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. ORG Wealth Partners LLC bought a new position in Vanda Pharmaceuticals during the third quarter valued at about $40,000. China Universal Asset Management Co. Ltd. raised its holdings in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares in the last quarter. XTX Topco Ltd bought a new position in Vanda Pharmaceuticals during the second quarter valued at about $75,000. Intech Investment Management LLC bought a new position in Vanda Pharmaceuticals during the third quarter valued at about $84,000. Finally, SG Americas Securities LLC raised its holdings in Vanda Pharmaceuticals by 88.5% during the third quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 9,580 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.